Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option ; volume:20 ; number:03 ; year:2021 ; pages:316-318
World Journal of Nuclear Medicine ; 20, Heft 03 (2021), 316-318
- Beteiligte Personen und Organisationen
-
Mileva, Magdalena
Wimana, Zéna
Flamen, Patrick
Karfis, Ioannis
- DOI
-
10.4103/wjnm.WJNM_120_20
- URN
-
urn:nbn:de:101:1-2022051210355584651578
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mileva, Magdalena
- Wimana, Zéna
- Flamen, Patrick
- Karfis, Ioannis
Ähnliche Objekte (12)
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Somatostatin receptor scintigraphy in sarcoidosis
Detection of Abdominal Lymph Node Metastasis from Pancreatic Neuroendocrine Tumor by Somatostatin Receptor Scintigraphy: Comparison with Somatostatin Receptor Type 2 Immunostaining
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Somatostatin receptor based hybrid imaging in sarcoidosis
Somatostatin receptor PET/CT in the management of patients with neuroendocrine tumors
Membrane-displayed somatostatin activates somatostatin receptor subtype-2 heterologously produced in Saccharomyces cerevisiae
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
New radiolabelled somatostatin receptor ligands for diagnosis and therapy
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Somatostatin receptor scintigraphy in sarcoidosis
Detection of Abdominal Lymph Node Metastasis from Pancreatic Neuroendocrine Tumor by Somatostatin Receptor Scintigraphy: Comparison with Somatostatin Receptor Type 2 Immunostaining
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Somatostatin receptor based hybrid imaging in sarcoidosis
Somatostatin receptor PET/CT in the management of patients with neuroendocrine tumors
Membrane-displayed somatostatin activates somatostatin receptor subtype-2 heterologously produced in Saccharomyces cerevisiae
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
New radiolabelled somatostatin receptor ligands for diagnosis and therapy
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Somatostatin receptor scintigraphy in sarcoidosis
Detection of Abdominal Lymph Node Metastasis from Pancreatic Neuroendocrine Tumor by Somatostatin Receptor Scintigraphy: Comparison with Somatostatin Receptor Type 2 Immunostaining
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Somatostatin receptor based hybrid imaging in sarcoidosis
Somatostatin receptor PET/CT in the management of patients with neuroendocrine tumors
Membrane-displayed somatostatin activates somatostatin receptor subtype-2 heterologously produced in Saccharomyces cerevisiae
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney